Free Trial

This company has been marked as potentially delisted and may not be actively trading.

2seventy bio (TSVT) Stock Forecast & Price Target

2seventy bio logo
Get the Latest News and Ratings for TSVT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for 2seventy bio and its competitors.

Sign Up

TSVT Analyst Ratings Over Time

TypeCurrent Forecast
7/23/24 to 7/23/25
1 Month Ago
6/23/24 to 6/23/25
3 Months Ago
4/24/24 to 4/24/25
1 Year Ago
7/24/23 to 7/23/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
1 Buy rating(s)
4 Buy rating(s)
Hold
3 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$5.00$5.00$5.60$12.43
Forecasted UpsideN/AN/A12.22% Upside171.96% Upside
Consensus Rating
Hold
Hold
Hold
Moderate Buy

TSVT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TSVT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

2seventy bio Stock vs. The Competition

Type2seventy bioMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.81
2.53
Consensus RatingHoldModerate BuyModerate Buy
Predicted UpsideN/A8,517.17% Upside10.20% Upside
News Sentiment Rating
Neutral News

See Recent TSVT News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/10/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingSell (E+) ➝ Sell (D-)
3/14/2025Morgan Stanley
3 of 5 stars
Matthew Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight ➝ Equal Weight$6.00 ➝ $5.00+1.01%
3/11/2025Leerink Partnrs
1 of 5 stars
D. Graybosch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
3/11/2025Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Daina Graybosch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$9.00 ➝ $5.00+78.57%
6/27/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.00+28.53%
6/6/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Sell$5.00 ➝ $2.00-56.14%
5/9/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Newman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/8/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$9.00 ➝ $12.00+117.79%
1/31/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Market Perform
9/12/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 11:54 AM ET.


TSVT Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for 2seventy bio is $5.00, with a high forecast of $5.00 and a low forecast of $5.00.

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 2seventy bio in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TSVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TSVT, but not buy additional shares or sell existing shares.

2seventy bio has been rated by research analysts at Weiss Ratings in the past 90 days.

Analysts like 2seventy bio less than other "medical" companies. The consensus rating for 2seventy bio is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TSVT compares to other companies.


This page (NASDAQ:TSVT) was last updated on 7/23/2025 by MarketBeat.com Staff
From Our Partners